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Abstract Understanding and determining levels of
lysophospholipids (LPLs) is of increasing interest to the
bioanalytical community as they may be targeted for prepara-
tive removal as a matrix interference or as a lead substance as a
biomarker of disease. Studies monitoring levels of LPLs have
used a range of approaches for quantitation whereby those
using an internal standard have used either deuterated ana-
logues of the target LPL or alternative LPLs containing an
odd number of carbon atoms within its chain, which can be
expensive and difficult to distinguish with other LPLs, respec-
tively. A structural analogue, miltefosine, was investigated as
a novel internal standard to quantify a selection of
lysophosphatidylcholines (LPCs) of clinical interest. A re-
verse phase C18 LC-MS/MS method was characterised for
16:0-LPC, 18:1-LPC and 18:0-LPC, showing good sensitivity
and linearity for all compounds, with limit of detection (LOD)
values <1 μg/mL and R2 ≥ 0.97. Quality control (QC) samples
were studied to determine accuracy and precision of the meth-
od, with values <15% variation for each compound at multiple
concentrations. As an example application, we have used this
method to detect the amount of LPC breakthrough following
solid phase extraction (SPE) of plasma to quantify LPCs as a
target species and to remove them as matrix interferences un-
der various conditions typical to clinical work. This study
showed that changes in sample pH could adversely affect
the capture of the LPCs and their contribution as matrix inter-
ferences, with 3.6 μg/mL of 18:1-LPC observed following
plasma extraction.
Keywords Lysophosphatidylcholine quantitation . Liquid
chromatography-mass spectrometry .Miltefosine . Solid
phase extraction . Plasma
Introduction
Phospholipids (PLs) are the primary component of cell mem-
branes with a characteristic structure and function. Each type
of PL consists of a fatty acid tail(s), a linker group (such as
glycerol or sphingosine) and a polar head group containing
phosphate [1]. Fatty acids can be of a range of carbon chain
lengths (e.g. C4-C36) [1] and the polar head group can contain
various chemical structures, including choline, ethanolamine
and inositol groups. These alternate structures provide great
variation in the types of PLs observed in biological samples.
Phospholipids are degraded naturally to repair cell membranes
using lipolytic enzymes such as phospholipase A; these can
remove a single fatty acid forming a lysophospholipid (LPL)
of related type (see Fig. 1 for example LPLs). Quantifying
levels of PLs and their LPL constituents in biological samples
are of increasing interest to the bioanalytical community as
these molecules can often interfere with the analytical
methods employed for detecting target substances such as
pharmaceuticals. Liquid chromatography-mass spectrometry
(LC-MS) has become the gold standard method of detection
and quantitation of non-volatile analytes at trace levels due to
its inherent specificity and sensitivity. For analytes such as
pharmaceuticals, atmospheric pressure ionisation (API)
methods such as electrospray ionisation (ESI) are often used,
especially for analyses in biological samples. Accurate
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analysis of target analytes within complex biological samples
is often difficult without prior preparation or separation of the
sample when using this approach asmore abundant species, or
those that are more amenable to ESI conditions can often
mask and interfere with the detection of the target analyte.
Phospholipids [2–4] and LPLs [3, 4] are examples of ‘matrix
interference’ that can affect the reliable detection of target
analytes in biological samples. There are many noted ap-
proaches to reduce their impact on the analysis by removal
through sample preparation with an extensive review of ma-
trix interference available in the literature [5]. Understanding
the levels of lipids, particularly LPLs, is important to estimate
the amount of LPL ‘break-through’ when evaluating sample
preparation technology and for clinical applications where
they may be used as biomarkers of disease, including moni-
toring lipolytic enzyme activity and as physiological messen-
ger molecules within biochemical signalling pathways.
It is still unclear as to the absolute levels of PLs and LPLs
and their various sub-types and this presumably is made more
challenging by the interconversion of these lipids that occurs
naturally. However, PL concentrations within human plasma
have been reported at levels of 1–3 mg/mL [6–8] with those
containing a choline head group (i.e. phosphatidylcholine)
being the most abundant contributing to approximately 70%
[8–10]. Of the glycerophospholipids, the most common chain
lengths observed are those containing a saturated C16 or C18
chain and an unsaturated C18 to C20 chain [1]. Therefore, it is
understandable why past literature has reported relatively high
abundances of lysophosphatidylcholine (∼3.2% of lipid phos-
phorous detected in plasma) [10] and in particular, a bias in
forming those of C16 and C18 chain lengths (i.e. C16:0,
C18:0, C18:1, C18:2) in various biological samples [8,
11–13]. However, this landscape of published data has been
accumulated using differing methods of detection and quanti-
tation meaning that a range of reported levels remain and
could be further influenced by enzyme activity and association
with other biomolecules, such as albumin [14]. More recent
analytical methods for LPLs have employed hyphenated mass
spectrometry techniques and in particular, hydrophilic interac-
tion liquid chromatography- or normal phase liquid
chromatography-mass spectrometry (LC-MS) using ESI [15,
16]. However, these conditions may not necessarily be suited
to other target analytes (i.e. pharmaceuticals), and prolonged
operation using simple conditions typical for reverse phase
methods in clinical analyses (water and acetonitrile solvents)
have shown evidence of LPC contamination and carryover
within the LC system (data acquired in house). The studies
monitoring levels of LPCs have used a range of approaches to
quantify absolute amounts whereby those adopting an internal
standard method have used either deuterated analogues of the
target LPC or LPCs containing an odd number of carbon
atoms within its chain. Unfortunately, both approaches have
limitations and can adversely affect the implementation of
these methods. For example, deuterated analogues are often
synthesised through bespoke methods resulting in a high pur-
chase cost. Also it is often challenging to maintain the integ-
rity of the deuteratedmaterial with the possibility of deuterium
exchange under certain experimental conditions [17, 18]. For
odd numbered chain LPCs, there are concerns regarding the
reliability of assigning the identity of various LPCs for quan-
titation as there are a number that are isobaric when detected
by MS and potentially when using LC too [16]. Given these
limitations, there remains a need for an alternative internal
standard that may be used for LPC quantitation and is the
subject of this paper.
Miltefosine or hexadecyl phosphocholine is a structural
analogue of 16:0-LPC without a glycero-linking group be-
tween the phosphocholine head group and alkyl chain (see
Fig. 1). Unlike deuterated analogues of LPCs, miltefosine is
available at relatively low cost and has a similar hydrophobic-
ity (logP) to common LPCs (e.g. 16:0-LPC, 18:0-LPC, 18:1-
LPC). Admittedly, this compound is a therapeutic andmay not
have the uniqueness of deuterated material; however, it is
administered specifically for the treatment of the parasitic dis-
ease, leishmaniasis [19], within developing countries and is
unlikely to be in the majority of samples for clinical study. A
validated reverse phase LC-MS method is available for
Fig. 1 Chemical structure of the lysophosphatidylcholines (1-palmitoyl-
sn-glycero-3-phosphocholine (16:0-LPC), 1-stearoyl-sn-glycero-3-
phosphocholine (18:0-LPC), 1-oleoyl-sn-glycero-3-phosphocholine
(18:1-LPC)) and a structural analogue, miltefosine (internal standard),
investigated in this study
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miltefosine, but this is concerned with determinations as the
target compound rather than using it as an internal standard for
LPC quantitation [19]. To the best of the authors’ knowledge,
the latter has yet to be investigated and published. To show the
usability of this approach, we have evaluated miltefosine for
quantifying a range of LPCs of clinical interest using an LC-
MS/MS method compatible in detecting both LPCs as the
target analytes and a selection of example pharmaceuticals
which may be subject to matrix interference from the presence
of LPCs. For proof of application within a clinical scenario,
we have also used this method to detect the absolute amounts
of LPCs in control plasma matrix which have been carried
through a solid phase extraction (SPE) procedure typically
used for clinical and pharmaceutical methods.
Experimental
Instrumentation
Sample separation was carried out using a Surveyor
autosampler and an MSPumpPlus (Thermo Fisher Scientific,
Runcorn, UK) LC system on a reverse phase Thermo Fisher
Scientific Hypersil Gold LC column (1.0 × 100 mm, 5 μm)
operated with a Hypersil guard cartridge, suitable for general
separations. Mass spectrometry detection was performed
using an LCQ ion trap (Thermo Fisher Scientific, Hemel
Hempstead, UK) operated using an ESI source in positive
mode. Instrument control and data analysis were carried out
using Xcalibur 2.0.7 software with data processed using both
the Quan Browser Xcalibur tool and Microsoft Excel.
Chemicals and materials
All standard reference materials, 1-palmitoyl-sn-glycero-3-
phosphocholine (16:0-LPC), 1-stearoyl-sn-glycero-3-
phosphocholine (18:0-LPC), 1-oleoyl-sn-glycero-3-
phosphocholine (18:1-LPC), miltefosine, propranolol, di-
phenhydramine and loratadine, had a purity of ≥99%, with
the exception of miltefosine, which was ≥98% and were pur-
chased from Sigma-Aldrich (Poole, UK). Solid phase extrac-
tion (SPE) cartridges containing C18 sorbent were provided
by Porvair Sciences (Wrexham, UK). Plasma matrix contain-
ing EDTA anticoagulant was obtained from Seralab (West
Sussex, UK) with solvents, methanol and water (both HPLC
grade) from Fisher Scientific (Loughborough, UK).
Ammonium solution (10% in water) was sourced from
Sigma-Aldrich (Poole, UK) and formic acid from Fisher
Scientific (Loughborough, UK); these were used for pH mod-
ification of the LC mobile phase and for sample modification
for SPE.
Stock solutions, calibration standards and quality control
samples
Due to the limited amount of LPC standard material,
stock solutions were prepared at 1 mg/1.5 mL concentra-
tions in a 50:50 mixture of solvents used for the LC
mobile phase (10 mM ammonia in 70:30 methanol/
water (A), and 10 mM ammonia in methanol (B)).
Calibration standards were made from the stock solutions
as a mixture in 50:50 mobile phase solution containing
LPCs and the internal standard (IS), miltefosine, at con-
centrations ranging 5.3–124.0 μg/mL (16:0-LPC), 5.3–
78.7 μg/mL (18:0-LPC), 5.3–52.0 μg/mL (18:1-LPC),
with each standard containing 6.7 μg/mL of miltefosine.
Standard blanks (a ‘double blank’ and an ‘internal stan-
dard blank’, S0) were also included within the quantita-
tive evaluation to assess the presence of carryover and
contamination during sample preparation. The internal
standard blank, S0, was also used to determine the limit
of detection (LOD) for the method. For method evalua-
tion for quantitation, quality control samples (QCs) were
prepared in the same fashion as the calibration standards
at a low, mid and high concentration within the calibra-
tion range (i.e., 37.3, 74.7, 124.0 μg/mL (16:0-LPC),
32.0, 53.3, 78.7 μg/mL (18:0-LPC), 26.7, 36.0,
52.0 μg/mL (18:1-LPC)) with each containing 6.7 μg/
mL of miltefosine.
Solid phase extraction (SPE)
For initial proof of principle of LPL capture and break-
through for a typical clinical application, a Microlute
C18 30 mg, 1.5F frit 96-well plate was tested under
different pH conditions (acid (0.1% v/v formic acid), ba-
se (0.1% v/v ammonia) and neutral) using solvent sam-
ples spiked with LPC and an example complex clinical
matrix, plasma. Solvent (water) samples were spiked at
appropriate concentrations of LPCs at the upper end of
the expected concentration range for plasma (i.e. 16:0-
LPC 117.3, 18:0-LPC 53.3, 18:1-LPC 32.0 μg/mL).
The spiked solvent sample or plasma was dispensed as
a 125 μL volume onto the cartridge along with 375 μL
of methanol (with or without pH modifier) to encourage
protein precipitation prior to elution. After application,
the sample mixture was eluted under positive pressure,
collecting the eluent for concentration and solvent ex-
change via evaporation. Dried extracts were reconstituted
using the 50:50 mobile phase mixture containing
miltefosine internal standard ready for analysis by LC-
MS. Break-through of LPC and performance of the C18
SPE cartridge were determined using the percentage re-
covery of LPC in the extract. A matrix effect measure-
ment was also determined to assess the variation in
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signal for individual LPCs and miltefosine caused by
matrix interference from the co-extractives (including
other LPCs).
Liquid chromatography conditions
Mobile phases consisted of 10mM ammonia (pH 10) in 70:30
methanol/water (A) and 10 mM ammonia in methanol (B).
Reverse phase chromatography was carried out using the
Hypersil Gold column operated with a guard cartridge of the
same material using these solvents as a gradient programme at
50 μL/minute. Starting conditions consisted of 10% B and
were held for 2 min following injection of the sample. The
solvent gradient was increased from 10% B to 70% B over
7.5 min and then to 100% B until 17.5 min. The column was
washed in 100% B over 5 min and returned to 10% B over
1 min. The column was conditioned at the starting solvent
mixture of 10% B for 13 min ready for the next injection.
Samples were injected as 5 μL volumes using a partial loop
injection mode and kept at 4 °C while on the autosampler tray.
A wash (and flush) solvent of 50:50 A/B mobile phase was
used for the needle, syringe and loop at a volume of 750 μL
for each injection.
Mass spectrometry conditions
Data was acquired online using ESI operating in positive ion
mode, at 4.5 kV with a capillary temperature and voltage of
200 °C and 14 V, respectively. A sheath gas flow of 60 (arbi-
trary units) was used to aid desolvation in ESI. Data was
acquired as a full mass scan over a mass range of m/z 100–
750, product ion scan (for determining fragment ions where
appropriate) and selected reaction monitoring (SRM) for
quantitation. Final SRM transitions can be found in Table 2.
Data processing
Mass spectrometry data was processed using Xcalibur 2.0.7
using the ISIS algorithm and Quan Browser tool to obtain
peak area and other relevant statistics. Further data processing
not possible in Quan Browser was undertaken manually using
Microsoft Excel 2007. Quality control (QC) samples were
used with the calibration standards to evaluate the quantitative
ability of the method tested. For typical figures of merit for
quantitation (i.e. accuracy, precision and LOD), the following
equations and definitions were used:
Accuracy ¼ calculated concentration−true concentration
true concentration
 100
Precision ¼ standard deviation of calculated concentration
mean calculated concentration
 100
LOD ¼ 3 Standard deviation of the concentration of the blank sample
All other equations (and calculations) used will be de-
scribed in the relevant sections with references.
Results and discussion
Analyte identification by mass spectrometry
Each LPC species and the internal standard, miltefosine, were
identified according to the m/z corresponding to the monoiso-
topic mass of the protonated molecules; 496.5, 522.5, 524.5
and 408.5 were observed as primary ion species for 16:0-LPC,
18:1-LPC, 18:0-LPC and miltefosine, respectively (see
Table 2). Product ion scans obtained from previous in-house
work for the precursor molecule ions of LPCs showed primary
fragment ions attributable to a loss of 18 mass units, generat-
ing ions at m/z 478.0, 504.0 and 506.0 for 16:0-LPC, 18:1-
LPC and 18:0-LPC, respectively, presumably from a loss of
water from a hydroxyl group within the glycerol section of the
structure. Miltefosine however did not show this loss of water
but a primary fragment ion also typical with LPCs at m/z 184,
consistent with the phosphatidylcholine head group. These
product ions were chosen to test the quantitative method
using selected reaction monitoring (SRM) as shown in
Table 2.
Characterisation and optimisation of liquid
chromatography method
Typical methods for separating LPCs consist of water and
acetonitrile mixtures [4, 18]. Unfortunately, following repeat-
ed application of high concentration standards to evaluate the
chromatography, carryover was observed, particularly for the
18:0-LPC species. Given this, alternative injection wash vol-
umes and solvents were evaluated but little improvement was
observed. An alkali (pH10) water/methanol mobile phase
method was investigated [19] showing near baseline separa-
tion with a relatively broad solvent gradient and no evidence
of carryover. This solvent system was optimised to increase
sample throughput yet maintain the chromatographic separa-
tion; with these chromatographic conditions, the column wash
stage could be shortened to 5 min without experiencing
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carryover further decreasing the analysis time for each sample.
For the envisaged clinical application, the initial gradient con-
ditions were kept at a low elution strength to accommodate
more polar target species, whereby this method could be used
as a multi-residue approach for LPCs and more polar chemis-
tries. This was tested using a selection of three common phar-
maceuticals as example target analytes (propranolol, diphen-
hydramine and loratadine) and these chromatographic condi-
tions proved suitable for the analysis showing baseline sepa-
ration and good peak shape (see Fig. 2).
The chromatographic behaviour of the mobile phase sys-
tem was evaluated to ensure the separation of the compounds
was mainta ined over severa l days of opera t ion.
Chromatography was monitored by injecting a sample repeat-
edly on two different days; this showed changes in retention
time and relative retention per day of %CV <0.92% on day 1
and <2.72% on day 2. To describe the reproducibility of ana-
lyte retention, an F-test calculation was used to compare data
on day 1 and day 2. After 3 days, the mean retention time did
appear to increase and this was confirmed following the ap-
plication of an appropriate F-test. However, as this was ob-
served for all analytes, it had little impact on the separation
and the method was investigated further (without modifica-
tion) regarding its potential for quantitation.
As expected for reverse phase column chemistry, the ana-
lyte retention coincided with lipophilicity (log P) with 18:0-
LPC showing the longest retention time consistent with a
greater expected interaction on the column. Miltefosine is
structurally similar to LPCs but does not contain a glycero-
connecting group consistent within LPCs. This considerably
affects the calculated log P of the structure (=3.58); however,
this could be advantageous with miltefosine likely to elute
within the range of the LPCs chosen for this work. Upon
further study, this was confirmed showing a retention time
between 18:1- and 18:0-LPC. Details of lipophilicity and
chromatographic separation (retention times) can be found in
Table 1. With the chromatographic method, all the pharma-
ceuticals eluted at relatively early retention times as expected.
Method evaluation for quantitation
To ensure that the chromatographic peak observed is repre-
sentative of the amount injected on column, it is essential that
a sufficient number of mass spectra are recorded during the
relevant elution (retention) time for the analyte of interest.
Typically, this will be in the order of 10–15 data points (mass
spectra) per chromatographic peak. To achieve this, a balance
is often sought between mass scan parameters (i.e. the speed
of acquisition, whereby SRM scans are generally less time
consuming) and chromatographic separation. Hence, where
possible, quantitative methods will typically employ an
SRM approach to achieve sufficient accuracy of chromato-
graphic peak shape; this with added gains in sensitivity from
this scan type enable sensitive and selective quantitation with
a good degree of accuracy. As the number of target analytes
increases, the number of SRM scans will also increase. When
performed sequentially, this can limit the number of relevant
data points achieved during the chromatographic peak for the
target SRM. An approach to overcome this is to segment the
acquisition method, only recording those scans specific to the
analytes eluting at relevant times (in this case a full mass scan
for screening of analyte transformation products and relevant
Fig. 2 Extracted ion chromatograms of example pharmaceuticals, 16:0-LPC, 18:1-LPC and 18:0-LPC and miltefosine (internal standard)
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SRM(s) for quantitation). However, as previously mentioned,
this is reliant on stable chromatographic conditions to capture
the LC peak. Limited sampling points (mass spectra) during
chromatographic method development highlighted that this
segmented approach would be necessary as a multi-residue
method. When applied, this segmented acquisition, recording
the screening full mass scan and the SRMs for the relevant
analyte class (i.e. pharmaceuticals or LPCs) was deemed suit-
able, achieving at least 15 data points across the chromato-
graphic peak.
Injection repeatability and reproducibility of miltefosine
for use as an internal standard
The aim of an internal standard is to normalise for any changes
in ionisation during the analysis and is particularly important
for techniques that are prone to interference from other
analytes present in complex samples. Chromatography can
help alleviate this matrix interference but may not completely
remove it, and for applications such as quantitation, account-
ing for this effect is key to accurate measurement. However,
isotopically labelled analytes are often very expensive and
previously used structural analogues of LPC can be difficult
to distinguish from other LPCs, particularly if they are not
resolved by the chromatographic method [16]. Miltefosine is
an alternative structural analogue, showing sufficient differ-
ences in mass for selectivity but a similar lipophilicity to the
target LPCs of this study (see Table 1). The repeatability and
reproducibility of the miltefosine signal was monitored by
injecting a sample repeatedly on two different days. The
SRM chromatogram was integrated to obtain the chromato-
graphic peak area for each run and this showed little change
per day with a %CV 5.56% on day 1 and 9.39% on day 2.
Given the limited fluctuation in the ionisation of miltefosine
under these chromatographic conditions (and an appropriate
retention time), this was tested further for the quantitation of
the LPCs as a possible internal standard. This was monitored
throughout the quantitative work with the LPCs as peak area
ratio (please see Table S4 and S5 of Electronic Supplementary
Material (ESM)).
Selectivity
Blank samples (both a ‘double blank’ and a blank containing
internal standard only, S0) were used judiciously throughout
the batch to detect the presence of carryover and ensure the
selectivity of the method. These samples were made from the
same matrix as the calibration standards and quality control
samples (QCs) to ensure their accuracy. Unlike some of the
earlier method development work with traditional reverse
phase acetonitrile-based LC methods, there was good selec-
tivity using the chosen SRM transitions and no evidence of
carryover at the relevant retention times.
Table 2 Mass spectral data acquisition information and quantitative data (dynamic range, linearity represented by the coefficient of determination, R2,
limit of detection (LOD), mean accuracy and precision) for each lysophosphatidylcholine (16:0-LPC, 18:1-LPC, 18:0-LPC) and the internal standard,
miltefosine (N = 5)
Compound Precursor i
on (m/z)
Fragment
ion (m/z)
SRM transition (m/z) Dynamic range
(μg/mL)
Linearity (R2) LOD (μg/mL) Mean Accuracy
(%)
Precision
(%)
QC1 QC2 QC1 QC2
16:0-LPC 496.5 478.0, 184.0 496.5–478.0 5.3–100.0 0.9698 0.15 7.34 −8.03 9.34 4.09
18:1-LPC 522.5 504.0, 184.0 522.5–504.0 5.3–44.0 0.9783 0.06 −5.66 −11.14 8.19 3.57
18:0-LPC 524.5 506.0, 184.0 524.5–506.0 5.3–62.7 0.9819 0.40 5.24 −3.84 10.20 4.60
Miltefosine (IS) 408.5 184.0, 125.0 408.5–184.0 – – – – – – –
Table 1 Physiochemical information and chromatographic data for each lysophosphatidylcholine (16:0-LPC, 18:1-LPC, 18:0-LPC) and the internal
standard, miltefosine (N = 10 for day 1, 5 for day 2)
Compound Molecular formula MW Log P Mean retention time
(minutes)
Mean adjusted
retention time
(minutes)
Retention time
precision (minutes)
Adjusted retention time
precision (minutes)
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
16:0-LPC C24H50NO7P 495.63 2.84 15.59 16.78 14.46 15.45 0.46 2.23 0.51 2.54
18:1-LPC C26H52NO7P 521.67 3.38 16.30 17.51 15.18 16.18 0.58 2.31 0.68 2.63
18:0-LPC C26H54NO7P 523.68 3.90 18.44 19.66 17.32 18.33 0.59 1.94 0.63 2.19
Miltefosine (IS) C21H46NO4P 407.57 3.58 17.44 19.02 16.32 17.70 0.76 2.42 0.92 2.72
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Statistical testing for homoscedasticity of calibration data
To ensure that correct regression statistics are used to accu-
rately describe the relationship between response (or relative
response to the internal standard) and concentration of the
target analyte, this should be tested with regards to homosce-
dasticity (or variance) within the concentration range used.
Often analytical techniques can show a greater degree of var-
iability in response (and therefore calculated concentration) at
the extremes of the values tested. This can affect the validity
and accuracy of the calibration graph in determining concen-
tration, particularly at low concentrations, and an appropriate
regression model in establishing this observed relationship
should be used. The calibration data acquired with this method
was processed by integrating the SRM chromatographic peak
for several standards of increasing concentration of each LPC.
These were injected in triplicate with a calibration set before
and after the QC samples to account for any changes in per-
formance of the method during the batch. Each standard in-
cluded a constant amount of the internal standard, miltefosine,
to normalise the LPC response. The calibration range was
based on approximate levels believed to be present in a typical
clinical (plasma or serum) sample and the proposed estimated
proportions described in previous publications [6–12].
Therefore, each LPC had different calibration ranges to ac-
count for these estimated proportions (see ‘Experimental’ sec-
tion and Table 2 for more details). All LPC peak areas were
normalised using the integrated peak area of miltefosine to
generate a relative response factor (RRF) for the calibration
graph. Using linear regression statistics, initial data showed
that linearity would be considerably improved with the omis-
sion of the top standard (S8) as this standard showed evidence
of signal saturation for all species. In the spirit of good prac-
tice, this standard was excluded from all further data analysis
and any study (unknown) samples of future analyses that are
detected at this concentration should be diluted for detection
within the linear range.
The adjusted calibration range was tested and evaluated in
terms of homoscedasticity (i.e. assessing the suitability of
equal weighting regression statistics, wi = 1) according to the
methods set out in Almeida et al. [20]. This was undertaken
using two methods: comparing a plot of the residual y-values
versus concentration, and testing statistical differences of the
variances of the lowest and highest standard in the calibration
range by performing an F-test. The initial results showed high
calculated F-values that exceeded the F-test statistic indicating
that the data was heteroscedastic for two of the LPCs, 16:0-
LPC and 18:0-LPC, with values of 21.65 and 38.51, respec-
tively. Given these results, the data was further tested and
compared with 1/x and 1/x2 weighting regression factors
(wi = 1/x and wi = 1/x
2) to establish if there was a more appro-
priate model to determine concentration. The calculated per-
centage relative error (%RE) of the back-calculated
concentrations was determined for the calibration standards.
This was tested by either comparing this value versus concen-
tration in the plot described above (whereby values should
reside as close to the x-axis as possible, see ESM Figs. S1-
S3) or by determining the total %RE, with the most appropri-
ate weighting factor having the lowest%RE. It proved prudent
to evaluate these weighting factors as the 1/x regression model
did provide the lowest %RE for the data set at −0.038, −0.036
and −0.002% for 16:0-LPC, 18:1-LPC and 18:0-LPC, respec-
tively (see ESM Tables S7-S9 for more information) and this
was chosen for quantifying the target LPCs.
Linearity
Using a weighted function of 1/x, improved regression statis-
tics were observed. All LPCs now showed a correlation coef-
ficient, (R) >0.98, and a coefficient of determination, (R2)
≥0.97, for a dynamic range of 5.3–100.0, 5.3–44.0 and 5.3–
62.7 μg/mL for 16:0-LPC, 18:1-LPC and 18:0-LPC, respec-
tively. These statistics indicate a good correlation for the re-
gression models describing the relative response of the LPCs
versus concentration (individual regression statistics are
included in Table 2 and the ESM Table S10 for further
information).
Accuracy
The accuracy of the calibration method to quantify levels of
each LPC was tested using QC samples at concentrations
within the established dynamic range (see ‘Experimental’ sec-
tion and Table 2 for details). These were analysed and the
relative responses inputted into the regression equation to de-
termine concentration. The difference between the calculated
concentration and the ‘true’ concentration (that was spiked)
was used to establish the accuracy of the quantitation. For
determining the level of ‘acceptable’ accuracy, criteria rele-
vant for clinical and pharmaceutical industries was followed
as guidance [21]; all QC samples should be within 15% of the
true concentration except at the limit of quantitation where it
may not exceed 20% accuracy. Given the ‘high’QC sample of
the original set now exceeded the adjusted calibration range of
the regression equation, it was subsequently omitted from fur-
ther data analysis. Of the remaining QC samples, a good level
of accuracy was observed with all five replicate samples for
each of the LPC compounds showing values less than the
threshold percentage. Subsequently, the mean accuracy values
for each LPC showed acceptable accuracy and are shown in
Table 2 with additional data present within the ESM. These
results are encouraging, indicating that this method is capable
of quantifying levels of each LPC using miltefosine as an
internal standard to a good degree of accuracy.
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Precision
This was established using the relative standard deviation
(%RSD) of the calculated concentrations for each QC level
for the LPCs (see Table 2). The results showed good precision
with both QC levels meeting the guidance criteria of 20 and
15% for low and mid QC concentration levels [21], respec-
tively, for all LPCs. As expected, the poorest precision was
observed at the lowest concentration QC (limit of quantita-
tion); however, this did not exceed 10% for the three LPCs.
This data shows that reliable measures of concentration may
be achieved using this method within the tested concentration
range.
Sensitivity
Sensitivity of the LC-MS method may be described through
several methods; the slope of the calibration graph or by sta-
tistically or empirically describing other figures of merit, such
as the limit of detection (LOD) using QC samples. The LOD is
considered as the ‘smallest measure…that can be detected
with reasonable certainty for a given analytical procedure’
[22]. Given that the regression statistics appear to be
heteroscedastic for a linear unweighted relationship, it was
deemed that transposing the standard error of the regression
(Sy/x) in place of the standard deviation of the blank for the
equation in the data processing section would be inappropri-
ate, and therefore the statistical method often employed un-
suitable [23]. Instead, the response of three replicate injections
of a standard blank containing internal standard (S0) was used
to calculate the LOD giving rise to concentrations of 0.15,
0.06 and 0.40 μg/mL for 16:0-LPC, 18:1-LPC and 18:0-
LPC, respectively. These values are in reasonable agreement
with the signal/noise of the first standard in the concentration
range showing average values above 100:1 for each LPC.
Applicability of established method
Lysophospholipids are considerable matrix interferences
when analysing other substances in clinical samples such as
plasma. Solvent samples spiked with LPCs and a pooled
plasma sample were extracted using the C18 solid phase car-
tridges under various pH conditions (acid, base and neutral) to
test LPC breakthrough and matrix interference. This approach
was chosen as a similar method had been the subject of phos-
pholipid removal for the extraction of clinical samples and the
detection of pharmaceuticals as the target substances [24], and
it may provide the opportunity to quantify LPCs as target
molecules, and how these may be removed as a matrix inter-
ference. Acid, base and neutral elution conditions are com-
monly employed in clinical applications to segregate com-
pound chemistries; however, this can often result in variations
in analyte/interference recovery and observed matrix effects.
For example, despite the anticipated strong interaction of the
LPCs on the C18 sorbent, pHmodification may alter retention
by subtly changing their chemistry (i.e. groups that are par-
tially dissociated), potentially leading to breakthrough. This
approachmay also show the applicability of the LC-MSmeth-
od described to detect and quantify LPCs in a scenario that is
of interest to clinical work. Spiked solvent samples/plasma
and the crash solvent (methanol with or without pH modifica-
tion) were drawn through the column and the resulting extract
evaporated to dryness. Each condition was tested in triplicate
with extracts reconstituted in 50:50 A/B mobile phase mixture
containing an appropriate amount of the internal standard,
miltefosine, to quantify any LPC detected. To confirmmethod
selectivity for the internal standard within the sample, ‘blanks’
were also extracted with no discernible signal detected above
the LOD. With the solvent sample extraction, less than 4%
recovery (break-through) was observed for each LPC under
acid, base and neutral conditions (see Table 3). Limited matrix
effects were observed for each LPC and miltefosine, with
values typically within 94–102, 83–88 and 100–108% for
acid, base and neutral conditions, respectively. Within plasma
extracts 16:0-LPC was observed above the LOD for both
acidic and basic extractions at 18.8 and 0.3 μg/mL, respec-
tively, indicating the SPE sorbent ability to capture endoge-
nous LPC had been compromised if we consider the estimated
concentrations of total LPC in plasma (i.e. 3.2% [10] of 1–
3 mg/mL [6–8]). Given the relative abundance estimations of
the LPCs from previous literature, it was anticipated that 16:0-
LPC would be most likely to be observed if the sorbent
Table 3 Mean percentage matrix
effects and recovery of LPCs and
miltefosine calculated using
spiked solvent samples following
C18 SPE with or without pH
modification (N = 3)
Compound Mean matrix effects and recovery of LPC detected in spiked solvent extract (%)
Acid (0.1% formic acid) Base (0.1% ammonia) Neutral
Matrix effects Recovery Matrix effects Recovery Matrix effects Recovery
16:0-LPC 97.06 0.81 83.18 0.66 101.04 3.14
18:1-LPC 94.70 0.34 83.67 0.35 104.67 0.69
18:0-LPC 94.50 0.16 84.97 0.15 100.38 0.11
Miltefosine (IS) 102.74 0.14 87.88 0.09 108.00 0.14
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became saturated, followed by 18:0-LPC and 18:1-LPC.
While 18:0-LPC was also observed under acidic conditions
at a calculated concentration of 3.6 μg/mL, 18:1-LPC ap-
peared to remain on the column with extract levels below
the detection limit of the method. Overall acidic extractions
did show a greater chance of LPC breakthrough and this
should be considered when performing extractions under
these conditions for other target substances. However, the data
did indicate that the extraction efficiency can be quite varied
with only some replicates showing breakthrough; a possible
cause of this may be differences in efficiency of protein crash
following pH modification and competition on the SPE sor-
bent for LPC retention.
LPLs are of interest to the clinical community both as a
problematic class of biomolecules that can behave as a
matrix interference for analyses of clinical samples by
LC-MS/MS and as target messenger molecules that have
the potential to be used as biomarkers. Therefore there is a
developing need to quantify these lipids to ensure appro-
priate clean-up methods are in place when analysing other
target species by LC-MS and for monitoring disease state.
Current analytical LC-MS methods have limitations in-
cluding carryover of lysophospholipids, and limited selec-
tivity and high cost of internal standards chosen for quan-
titative work. Here we have developed and characterised a
novel approach to LPL quantitation using several
lysophosphatidylcholine (LPC) species common to clinical
samples as the test molecules. This method employs a
more cost effective, novel internal standard, a structural
analogue of LPC, miltefosine; to the best of the authors’
knowledge, this has not been published in this form or for
this application before. The analytical method has been
evaluated in terms of chromatographic stability and perfor-
mance for quantifying the selected LPCs. Data acquired
has shown a good level of sensitivity (within that required
for monitoring estimated clinical LPC levels), accuracy
and precision for quantitation. It has also been successfully
applied to a simple plasma extraction using SPE under a
range of conditions to detect the level of LPC break-
through for a common clinical scenario, providing an ex-
ample of target LPC quantitation and removal as a matrix
interference. These results suggest that miltefosine has the
potential to be used as a viable alternative internal stan-
dard for determining LPC concentrations and warrants fu-
ture testing in more challenging clinical applications.
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